FASEB SRC: Genetic Recombination and Genome Rearrangements

FASEB SRC:基因重组和基因组重排

基本信息

项目摘要

DESCRIPTION (provided by applicant): This application seeks partial support for the Federation of American Societies of Experimental Biology (FASEB) conference on Genetic Recombination and Genome Rearrangements to be held July 21-26, 2013 in Steamboat Springs, Colorado. The 2013 Conference will be the fifteenth in a series of highly successful bi-annual conferences devoted to these topics. This conference aims to join investigators studying many diverse aspects of genetic recombination, in a range of biological systems and with different experimental approaches. Presentations will introduce new and unpublished work on timely questions in the field and will include discussion from all participants. The FASEB conference provides unique opportunities for the exchange of information and technology that can be appreciated and exploited across the recombination field. DNA Recombination and Genome Rearrangements have a two-fold significance for cancer. First, many genes/proteins involved in the mechanisms and regulation of recombination have already been identified as tumor suppressor genes. Hence, studies with these genes/proteins are paramount for an improved understanding of the etiology of cancer and to develop critical biomarkers. Second, induction of systemic or localized DNA damage by chemotherapy or radiation, respectively constitute major modalities of anti-cancer treatment. The types of relevant DNA damages include DNA double-stranded breaks and interstrand crosslinks, and recombination is a central cellular pathway to repair such damage. Therefore, increased knowledge on the regulation and mechanism of these repair processes will also inform novel strategies of anti-cancer treatment leading to more efficacious treatment. Several timely issues will be discussed, including the role of the breast cancer susceptibility gene BRCA2 in the control of recombination and the role of recombination in repair of DNA damage caused by cancer treatment relevant drugs and radiation. Characterization of recombination and repair factors known to underlie human syndromes with propensity to cancer, premature aging, immune dysfunction and neurological degeneration will also be discussed, using mammalian and other model genetic systems. In addition, new insights from next generation sequencing approaches will be discussed. By emphasizing truly exceptional research in a modestly sized conference setting, the FASEB conference provides unique opportunities for the exchange of information, technology and perspective among new and established investigators in the recombination field.
描述(由申请人提供):本申请寻求对将于 2013 年 7 月 21 日至 26 日在科罗拉多州斯廷博特斯普林斯举行的美国实验生物学会联合会 (FASEB) 基因重组和基因组重排会议的部分支持。 2013 年会议将是专门讨论这些主题的一系列非常成功的两年一度的会议中的第十五次。本次会议旨在与研究人员一起,在一系列生物系统中采用不同的实验方法研究基因重组的许多不同方面。演讲将介绍有关该领域及时问题的新的和未发表的工作,并将包括所有参与者的讨论。 FASEB 会议为交流信息和技术提供了独特的机会,这些信息和技术可以在重组领域得到欣赏和利用。 DNA 重组和基因组重排对癌症具有双重意义。首先,许多参与重组机制和调控的基因/蛋白质已被鉴定为抑癌基因。因此,对这些基因/蛋白质的研究对于增进对癌症病因学的了解和开发关键的生物标志物至关重要。其次,通过化疗或放疗诱导全身或局部DNA损伤分别构成抗癌治疗的主要方式。相关DNA损伤的类型包括DNA双链断裂和链间交联,重组是修复此类损伤的核心细胞途径。因此,增加对这些修复过程的调节和机制的了解也将为抗癌治疗的新策略提供信息,从而实现更有效的治疗。将讨论几个及时的问题,包括乳腺癌易感基因BRCA2在控制重组中的作用以及重组在修复癌症治疗相关药物和辐射引起的DNA损伤中的作用。还将使用哺乳动物和其他模型遗传系统来讨论已知构成人类癌症、早衰、免疫功能障碍和神经退行性疾病倾向的重组和修复因子的特征。此外,还将讨论下一代测序方法的新见解。通过在中等规模的会议环境中强调真正杰出的研究,FASEB 会议为重组领域的新老研究人员之间交流信息、技术和观点提供了独特的机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wolf-Dietrich Heyer其他文献

Wolf-Dietrich Heyer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wolf-Dietrich Heyer', 18)}}的其他基金

Regulation of DNA double-strand break repair pathway choice
DNA双链断裂修复途径选择的调控
  • 批准号:
    10656805
  • 财政年份:
    2023
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10806624
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10019104
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10795314
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10241424
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10670239
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
Genome instability induced by homologous recombination
同源重组引起的基因组不稳定
  • 批准号:
    10437930
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
2015 Nucleic Acids Gordon Research Conference
2015年核酸戈登研究会议
  • 批准号:
    8892554
  • 财政年份:
    2015
  • 资助金额:
    $ 0.3万
  • 项目类别:
Functions of Rad51 Paralogs in Recombinational DNA Repair
Rad51 旁系同源物在重组 DNA 修复中的功能
  • 批准号:
    8890651
  • 财政年份:
    2011
  • 资助金额:
    $ 0.3万
  • 项目类别:
Functions of Rad51 Paralogs in Recombinational DNA Repair
Rad51 旁系同源物在重组 DNA 修复中的功能
  • 批准号:
    8237897
  • 财政年份:
    2011
  • 资助金额:
    $ 0.3万
  • 项目类别:

相似海外基金

FASEB SRC on Genetic Recombination and Genome Rearrangements
FASEB SRC 关于基因重组和基因组重排
  • 批准号:
    8978686
  • 财政年份:
    2015
  • 资助金额:
    $ 0.3万
  • 项目类别:
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
霍奇金淋巴瘤幸存者低剂量他莫昔芬可降低乳腺癌风险
  • 批准号:
    8090389
  • 财政年份:
    2010
  • 资助金额:
    $ 0.3万
  • 项目类别:
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
霍奇金淋巴瘤幸存者低剂量他莫昔芬可降低乳腺癌风险
  • 批准号:
    8707396
  • 财政年份:
    2010
  • 资助金额:
    $ 0.3万
  • 项目类别:
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
霍奇金淋巴瘤幸存者低剂量他莫昔芬可降低乳腺癌风险
  • 批准号:
    7878876
  • 财政年份:
    2010
  • 资助金额:
    $ 0.3万
  • 项目类别:
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
霍奇金淋巴瘤幸存者低剂量他莫昔芬可降低乳腺癌风险
  • 批准号:
    8270552
  • 财政年份:
    2010
  • 资助金额:
    $ 0.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了